Quarterly ResultMay 1, 2026, 05:17 PM
Zimmer Biomet Q1 Net Sales +9.3% to $2.09B; EPS $1.22
AI Summary
Zimmer Biomet Holdings, Inc. reported strong first-quarter 2026 financial results, with net sales increasing by 9.3% to $2.09 billion and diluted EPS rising 34.1% to $1.22. Operating profit also saw a significant increase of 27.7% to $373.2 million. The company continued its 2025 Restructuring Plan and integrated recent acquisitions of Paragon 28 and Monogram Technologies, which contributed to its segment performance.
Key Highlights
- Net Sales reached $2,086.7M in Q1 2026, a 9.3% increase from Q1 2025.
- Diluted Earnings Per Share (EPS) was $1.22 in Q1 2026, up 34.1% year-over-year.
- Operating Profit increased 27.7% to $373.2M in the first quarter of 2026.
- S.E.T. product category sales grew 19.5% to $562.2M in Q1 2026.
- International sales rose 10.3% to $877.4M for the three months ended March 31, 2026.
- Net cash used in financing activities was $369.2M in Q1 2026.
- Current portion of long-term debt increased to $1,175.9M as of March 31, 2026.
- The company repurchased $250.1M of common stock in Q1 2026.
Price Impact
More from ZBH